I love this story… it brings to mind the Indiana Jones-style teaser pitches about top-secret mineral riches in strange places that were so prevalent a decade ago in newsletterland… here’s a little taste: “This Secret Research Complex… “Hidden Away in a Small Town in Australia… “Is About to Reveal a “$66 Billion Breakthrough…” Wow, so […]
Articles
Who can resist that headline? Louis Navellier is peddling his Emerging Growth newsletter by promising a special report called The Stock of the Century… so, naturally, we wanna know what that stock is. And we don’t want to pony up $995 for an Emerging Growth subscription to find out, frankly — if we paid that […]
We’ve got a good backlog of teaser pitches to get to, as usual, but this one filtered to the top for our attention today — it’s an ad from David Fessler for his Oxford Resource Explorer newsletter (currently $79), and the ad seems mostly to have gotten folks’ attention because of a link from one […]
Today we have the attention-getting “Say NO to Lithium Stocks” headline from Dr. Kent Moors in an ad for his Energy Advantage newsletter… and, as you will probably have already guessed, it’s really more of a “Say No to Lithium Stocks (except for this awesome little one I want to sell you one)” ad. So, […]
Louis Basenese has a new ad promoting his VentureCap Strategist newsletter ($2,000 a year), and it gets our attention with lots of hot air about “White Oil” … which, he says, is explosive in both chemical terms and investment potential. Here’s a taste of the intro: “This new White Oil is spiking 9X faster than […]
This article was first posted on May 12, but readers keep asking about it so we have pushed it back to the top of the page for your edutainment. No, Tesla is not “betting it all” on this one little company, but there is, as always, a bit of truth behind the tease… and in […]
JR Crooks is fairly new in his role as editor at Global Resource Hunter, but the two teaser pitches he has sent out in the last few months have certainly caught the attention of our readers — the first one was for the silly “Pyramus Compound” and his special “black goo” replacement oil that the […]
First Published March 8 2016 This is not a brand-new ad, and it has been discussed by Gumshoe readers a few times — but apparently I’ve never written about it or looked closely at it, so we’ll remedy that today. And, of course, we’ll name the “secret” stocks being teased for you. Keith Kohl opens […]
This teaser ad has been around for a few months in various forms, but it continues to be among the most-queried pitches here at Stock Gumshoe, and there’s a big new push for this ad just today that’s generating even more questions — so I thought I’d toss you a quick reminder of the details […]
It’s been a few weeks since we had a heated teaser roll in from the Motley Fool, so today we’ll welcome the Foolies back to the fold — this time it’s an ad for their flagship Stock Advisor newsletter edited by Tom and Dave Gardner, and it’s all about profiting from the “Mobile Media Gold […]
This teaser for one of Andy Obermueller’s newsletters has been making the rounds for a while, but it has so many aggressive predictions in it that the questions about it roll in to Stock Gumshoe HQ pretty regularly … so let’s see if we can pick out a few of his hot “investment opportunities,” shall […]
The folks at the Oxford Club are launching a new service this week that they call Peak Energy Strategist, run by David Fessler, who I guess has been an energy analyst for them for a while … like many folks, he claims to have a special set of indicators that he uses, in this case […]
I’ve written probably far too many notes here about teasers from the esteemed Louis Navellier of late, but I can’t help it — his ads are making fairly huge promises (none yet kept), and they are arriving in a deluge. Perhaps ignoring them would be the saner path, but no one ever accused the Stock […]
Comments
I've seen few scenarios as embittering as PTN. I just believe mgmt told whopper-size lies to shareholders and we still d...
A $PTN buyout is plausible. Flibanserin (Addyi) was recently approved for FSD and bought by Valeant....
$PTN - - some observations from the presentation. > Slide 7: "Market analysts estimate global market > $2 billi...
Bizbanx -- this link gives a version of the 19-item FSFI questionnaire that was used for both bremelanotide and for flib...
I also read that alcohol is compatible with bremelanotide whereas it's contraindicated in patients on flibanserin (Addyi...
The New York Times reports that Sprout's flibanserin - once dubbed the pink viagra - has proved less than arousing. Mar...
$PTN. Was updating myself today on this stock, which has been discussed here from time to time, and am sharing in case ...
A most excellent point, Kenny. If one puts the best possible spin on PTN it's now easily worth more. The street view, ho...
The couple in Raleigh, NC, who bought and developed flibanserin are quixotic. The till may have little cutter in it when...
John Carroll at Fierce Biotech on the FDA's approval of Flibanserin: http://www.fiercebiotech.com/story/fda-blundered...
And on 06/05/15: Author: Dr. KSS, MD PhD Comment: Sogiam: you were asking about Palatin. This is a pure sucker's ral...
Rae -- agree with you on the merits, but note that it is not possible to invest directly in flibanserin even if one were...
FDA statement on flibanserin approval: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm Long $P...
Spelling correction: flibANSERIN. Hate it when that happens....
I have no medical background whatsoever, but I also strongly disagree with the acceptance of flibanserin. imo, at first...
THE REAL PROBLEM WITH FLIBANSERIN: http://www.newyorker.com/cartoons/daily-cartoon/daily-cartoon-friday-june-5th-female...
Interesting and very public battle going on about this drug, and the issues are at least as much politics and perception...
Kenny: and don't doubt flibanserin therapy won't cost at least $500/month and NOT be covered by third party payers. For ...
Kenny---I think much will depend on marketing, but I look at it this way. Flibanserin is premised on a notion that tweak...
Doc - in addition to the warning labels for flibanserin, I had read that the drug provides very modest results, specific...
According to briefing documents, the FDA will likely require physicians intending to prescribe flibanserin for female se...
Sogiam: you were asking about Palatin. This is a pure sucker's rally in its shares, as Sprout's flibanserin story has li...
https://soundcloud.com/bmjpodcasts/the-sex-drug-for-women?utm_source=feedburner-bmj.com+download&utm_medium=feed&utm_cam...
Doc, thanks for your comments and I'm so glad you let the poorly informed author know about PTN. Sprout has done a good ...
Frank: Thanks for asking about flibanserin. My honest view is that Boehringer was wise to divest itself of that product ...
Dr KSS ; as a follow up to PTN have you any thoughts on Sprout pharma 'Flibanserin' for HSDD?...